Phase 2a
CCMR Two: positive biological remyelination signal with metformin plus clemastine
Twenty-four weeks of metformin plus clemastine significantly reduced visual-evoked-potential latency, a finding consistent with remyelination. Visual function and disability did not improve over the study's short duration.
What this means clinically
This is one of the stronger human proof-of-concept signals, but not evidence that the treatment improves symptoms or reverses disability.
Source quality: Moderate to high • official academic headline results; full peer-reviewed publication pending
University / investigatorCambridge Clinical MS Research Group ↗